Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients

Cancer Genetics and Cytogenetics

Volumn 98, Issue 1, 1997, Pages 50-55

  Patino Garcia A ^a   Sierrasesumaga L ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; EWING SARCOMA; GENE AMPLIFICATION; GENE DELETION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOSARCOMA; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BONE NEOPLASMS; CARRIER PROTEINS; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EXONS; GENE DELETION; GENES, P53; HUMANS; OSTEOSARCOMA; POINT MUTATION;

EID: 0342437542     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(96)00397-4     Document Type: Article

References (27)

1. Toguchida, J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB (1992): Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199.
2. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP (1986): A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646.
3. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro T (1994): Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54:3042-3048.
4. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH (1994): A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
5. Serrano M, Hannon GJ, Beach D (1993): A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
6. Spruck CH, Gonzalez Zulueta M, Shibata A, Simoneau AR, Liu MF, Gonzales F, Tsai YC, Jones PA (1994): p16 gene in uncultured tumors. Nature 370:183-184.
7. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A (1995): CDKN2 (MTS1) tumor suppressor gene mutations in human tumor call lines. Oncogene 10:1061-1067.
8. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989): Mutations in the p53 occur in diverse human tumor types. Nature 342:705-708.
9. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991): Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
10. O'Rourke RW, Miller CW, Kato GJ, Simon KJ, Chen D-L, Dang C-V, Koeffler PK (1990): A potential transcriptional activation element in the p53 protein. Oncogene 5:1829-1832.
11. Antillón-Klüssmann F, García-Delgado M, Villa-Elízaga I, Sierrasesúmaga L (1995): Mutational activation of ras genes is absent in pediatric osteosarcoma. Cancer Genet Cytogenet 79:49-53.
12. Rogers BB, Alpert LC, Hine EA, Buffone GJ (1990): Analysis of DNA in fresh and fixed tissue by polymerase chain reaction. Am J Pathol 136:541-548.
13. Sun Y, Hildesheim A, Lanier AEP, Cao Y, Yao K-T, Raab-Traub N, Yang C-S (1995): No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene 10:785-788.
14. Hiort O, Wodtke A, Struve D, Zöllner A, Sinnecker GHG, German "Collaborative Intersex Study Group" (1994): Detection of point mutations in the androgen receptor gene using non-isotopic single strand conformation polymorphism analysis. Hum Mol Genet 3:1163-1166.
15. Hamelin R, Jego N, Laurent-Puig R, Vidaud M, Thomas G (1993): Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 8:2213-2220.
16. Børresen A-L, Hovig E, Smith-Sørensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH (1991): Constant denaturing gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 88:8405-8409.
17. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP (1996): Alterations of the p15, p16 and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86:136-142.
18. Enneking WF, Spanier SS, Goodman MA (1980): A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 153:106-120.
19. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sørlie T, Hovig E, Smith-Sørensen B, Montesano R, Harris CC (1994): Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3355.
20. Oliner JD, Kinzier KW, Meltzer PS, George DL, Volgestein B (1992): Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
21. Ladayi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH (1993): MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16-18.
22. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM (1993): The sensitivity of single strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 16:325-332.
23. Lerman L, Silverstein K (1987): Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol 155:482-501.
24. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995): Retinoblastoma-protein dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375:503-506.
25. Fults D, Brockmeyer D, Tullons MW, Pedone CA, Cawthon RM (1992): p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocitoma progression. Cancer Res 52:674-679.
26. Mazars R, Spinardi L, Beucheikh M, Simoriy-Lafontaine J, Jeanteur P, Theillet C (1992): p53 mutations occur in aggressive breast cancer. Cancer Res 52:3918-3923.
27. Fujimoto T, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sigumura T, Terada M (1992): Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res:393-398.